product summary
Loading...
company name :
HUABIO
product type :
antibody
product name :
CD47
catalog :
HA600104F
quantity :
100μl
price :
394.00 USD
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
1B1
reactivity :
human
application :
flow cytometry
more info or order :
image
image 1 :

Flow cytometric analysis of MCF-7 cells labeling CD47.
Cells were washed twice with cold PBS and resuspend. Then incubated for 1 hour at +4℃ with HA600104F CD47 (HA600104F, red, 1ug/ml) and Mouse IgG1 Isotype Control (iFluor™ 488, green, 1ug/ml). Unlabelled sample was used as a control (cells without incubation with primary antibody; black).
product information
SKU :
HA600104F
Target name :
CD47
Species reactivity :
Human
Applications :
FC
Conjugate :
iFluor™ 488
Immunogen :
Recombinant protein within human CD47 aa 19-141 (Extracellular).
Uniprot id :
Q08722>SwissProt: Q08722 Human
Host :
Mouse
Clone number :
1B1
Isotype :
IgG1
Size :
100μl
List Price :
394.00 USD
Storage Buffer :
Preservative: 0.02% Sodium azide
Constituents: 30% Glycerol, 1% BSA, 68.98% PBS
Form :
Liquid
Storage Instruction :
Shipped at 4℃. Store at +4℃ short term (1-2 weeks). It is recommended to aliquot into single-use upon delivery. Store at -20℃ long term.
Purity :
Immunogen affinity purified.
Product type :
Mouse monoclonal Antibody
Positive control :
MCF-7.
Molecular wt :
35 kDa
Subcellular location :
Cell membrane
Concentration :
2 mg/mL.
Recommended dilutions :
FC: 1:500
more info or order :
company information

HUABIO
Founded in 2007, HUABIO is dedicated to developing high-quality antibodies that advance innovation. We are passionate about the accuracy, efficiency, and consistency of our products. That is why we have invested in new production platforms, like recombinant rabbit monoclonals, alpaca nanobodies, and adopted aggressive QA standards to deliver cutting-edge antibodies with uncompromised quality.
We hope to see you at your next discovery!
We hope to see you at your next discovery!
related products
browse more products
questions and comments
